NEW ORLEANS — New data show sustained glycemic improvements and safety at 1 year in very young children with type 1 diabetes who used a tubeless hybrid closed-loop insulin delivery system, researchers reported.
Improved glycemic outcomes and safety in the initial 3-month pivotal study of the Omnipod 5 system (Insulet) in very young children persisted for an additional 9 months in an ongoing extension study, Daniel DeSalvo, MD, director of strategic collaboration at Texas Children’s Diabetes and Endocrine Care Center, said during a presentation at the American Diabetes Association